Published July 23, 2026
The first bellwether trial in the paraquat Parkinson's disease litigation never made it to opening statements. On January 27, 2026, the night before the trial was set to begin in Philadelphia's Court of Common Pleas, Syngenta reached a settlement with Bill Mertens, a 77-year-old retired landscaper who had used the company's paraquat-based herbicide Gramoxone for decades and was diagnosed with Parkinson's disease in 2021. The terms of the settlement were not disclosed.
Mertens's lead attorney, Aimee Wagstaff, told reporters at the time: "the parties have decided that resolution is the best path for this particular matter." The case had been closely watched because it was expected to be the first jury to hear evidence directly addressing whether paraquat exposure causes Parkinson's disease — a question central to the more than 8,000 lawsuits that had been filed against Syngenta by that point.
By settling on the eve of trial, Syngenta avoided a public jury verdict on causation at a moment when the timing was particularly sensitive: US regulators were actively reviewing paraquat's safety, and several state legislatures were considering bans on the chemical. A jury verdict — in either direction — could have shifted momentum in those parallel processes. Instead, the case joined a pattern that continued in the following weeks, as Syngenta went on to settle additional cases that had been heading toward trial without any paraquat case actually reaching a jury.
A settled bellwether case doesn't resolve the litigation for everyone — it resolves one plaintiff's individual case. Thousands of other paraquat Parkinson's claims remain active in the federal MDL in Illinois and in Pennsylvania state court, and the broader settlement framework that has since developed doesn't automatically cover people who haven't filed. If you or a family member has a history of paraquat exposure and a Parkinson's diagnosis, a free eligibility review can help clarify your options. Visit Atumio's Paraquat Lawsuit page or start a free case review.